Home > Insider Trading > Filing (0001493152-21-032897)

Filing Details

Accession Number:: 0001493152-21-032897
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-12-30 17:20:46
Reporting Period:: 2021-12-28

Accepted Time:: 2021-12-30 17:20:46
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
876343	Lineage Cell Therapeutics Inc.	LCTX	Biological Products, (No Disgnostic Substances) (2836)	943127919

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1771711	S. Gary Hogge	2173 Salk Avenue, Suite 200 Carlsbad CA 92008	Svp,Clinical & Medical Affairs	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Shares, No Par Value	Acquisiton	2021-12-28	185,000	$0.69	213,445	No	4	M	Direct
Common Shares, No Par Value	Acquisiton	2021-12-28	236,899	$2.11	450,344	No	4	M	Direct
Common Shares, No Par Value	Acquisiton	2021-12-28	79,689	$1.14	530,033	No	4	M	Direct
Common Shares, No Par Value	Disposition	2021-12-28	501,588	$2.45	28,445	No	4	S	Direct
Common Shares, No Par Value	Acquisiton	2021-12-29	9,250	$0.69	37,695	No	4	M	Direct
Common Shares, No Par Value	Disposition	2021-12-29	9,250	$2.49	28,445	No	4	S	Direct
Common Shares, No Par Value	Disposition	2021-12-29	28,445	$2.44	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Shares	Employee Stock Option (right to buy)	Disposition	2021-12-28	185,000	$0.00	185,000	$0.69
Common Shares	Employee Stock Option (right to buy)	Disposition	2021-12-28	236,899	$0.00	236,899	$2.11
Common Shares	Employee Stock Option (right to buy)	Disposition	2021-12-28	79,689	$0.00	79,689	$1.14
Common Shares	Employee Stock Option (right to buy)	Disposition	2021-12-29	9,250	$0.00	9,250	$0.69

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
259,000	2030-03-17	No	4	M	Direct
10,301	2028-02-11	No	4	M	Direct
32,811	2029-02-12	No	4	M	Direct
249,750	2030-03-17	No	4	M	Direct

Footnotes

The price reported is a weighted average. These shares were sold in multiple transactions at prices ranging from $2.40 to not more than $2.53. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
The 9,250 shares sold on 12/29/21, were all sold at a transaction price of $2.49.
The price reported is a weighted average. These shares were sold in multiple transactions at prices ranging from $2.42 to not more than $2.52. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
The reporting person was granted options on March 17, 2020, with an exercise price of $0.6919 per share to purchase up to 444,000 common shares of the issuer. One quarter of the options vested and became exercisable on March 17, 2021, the first anniversary of the grant date, and the balance vests in 36 monthly installments thereafter upon completion of each month of the reporting person's continuous employment with the issuer.
The reporting person was granted options on February 11, 2018, with an exercise price of $2.11 per share to purchase up to 247,200 common shares of the issuer. One quarter of the options vested and became exercisable on February 11, 2019, the first anniversary of the grant date, and the balance vests in 36 monthly installments thereafter upon completion of each month of the reporting person's continuous employment with the issuer.
The reporting person was granted options on February 12, 2019, with an exercise price of $1.14 per share to purchase up to 112,500 common shares of the issuer. One quarter of the options vested and became exercisable on February 12, 2020, the first anniversary of the grant date, and the balance vests in 36 monthly installments thereafter upon completion of each month of the reporting person's continuous employment with the issuer.